AzTrials
AzTrials

Quality of LifePMNCT05445453

Museum Prescription by a Physician for a Visit to the MBAM

A study testing Museum visit in people with Quality of Life and Social Isolation, run by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In recent years, museums have participated in the patient care journey by using art to enhance their quality of life and well-being. Since 2015, the Montreal Museum of Fine Arts (MMFA) and Dr. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Quality of Life, Social Isolation
What is being tested?
Museum visit
Could I receive a placebo?
No, everyone receives an active treatment
How many people
86 participants
Where
1 siteCanada
Study dates
27 Jun 2022to 22 Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • age 18 and over
  • having Internet access at home with an electronic device (computer, keyboard, or smartphone)
  • having no dementia
  • speaking English or French
  • committing to visiting the museum within 3 months of the prescription.

Who cannot join

  • individuals participating in a clinical trial at the same time, to avoid interference with the results of the intervention being studied in this protocol
  • individuals with dementia. There are no tests for dementia. The physicians involved in the pre-recruitment process are aware of the cognitive status of their patients. Therefore, they will be able to avoid offering the study to a patient with dementia if such a diagnosis appears in the medical file.

Trial locations and contacts

1 site in 1 country.

Canada1 site

  • CRIUGM

    Montreal, Quebec, H3W 1W5

Other trials in Canada

About this study

Official title: Museum Prescription by a Physician for a Visit to the Montreal Museum of Fine Arts: Assessment of Effects.

In recent years, museums have participated in the patient care journey by using art to enhance their quality of life and well-being. Since 2015, the Montreal Museum of Fine Arts (MMFA) and Dr. Beauchet have developed an Action-Research program exploring the effects of participatory art activities for community elders conducted at the MMFA, known as the Arts \& Longevity Lab (ALL). The mandate of ALL is to improve the well-being, quality of life and health (i.e. mental and physical state) of individuals and patients through the practice of visual arts activities (i.e. arts that produce objects perceived by the eyes).

Since 2019, the MMFA has developed in collaboration with Médecins Francophones du Canada museum visits prescribed by a primary care physician as a new intervention. Today, it is necessary to improve the knowledge on the effects of this museum visit prescription

The overall objective of this study is to examine the effects of a visit to the MMFA prescribed by a primary care physician on the mental health (well-being and quality of life) of patients living in Montreal.

Being tested
Museum visit
Keywords
Arts, Well-being, Mental Health
Medical subject headings
Social Isolation, Arts syndrome, Psychological Well-Being

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Museum visitOther

    The intervention is a visit of the MMFA. This visit can be done alone or accompanied.

    The visit of the MMFA is free for the patient.

Study groups in NCT05445453
Study groupRoleWhat they receive
InterventionExperimentalPhysicians participating in the research project will be able to prescribe a visit to the Museum to any of their patients for whom they deem this museum prescription necessary. Only patients who meet the inclusion criteria will be offered to participate in the research. If patients refuse or do not meet the inclusion criteria, they may be prescribed a museum visit but will not be offered the study. After obtaining informed consent, the patient will be asked to complete 2 sets of self-administered questionnaires: in the 2 days prior to the visit and in the 2 days following the MBAM visit.
Receives: Other: Museum visit

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quality of life

    Quality of life will be assessed using the EuroQol-5D (EQ-5D).

    EuroQol-5D is composed of two parts:

    • a five-question questionnaire with a score per question ranging from 1 (no problem) to 5 (severe problem), so that the sum ranged from 0 (no problem) to 25 (severe problem).
    • a visual analogue scale on participants' perceived health. This scale is numbered from 0 (i.e., the worst health the participant can imagine) to 100 (i.e., the best health the participant can imagine).

    This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

    Measured: 3 months

  2. Well-being

    Well-being will be assessed using the Warwick-Edinburgh Mental Well-being Scale (WEMWBS).

    The WEMWBS is a validated questionnaire composed by a 14-item positively worded scale and five response categories. It covers most aspects of positive mental health (positive thoughts and feelings).

    This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

    Measured: 3 months

Secondary outcomes (4)

  1. Physical Health Status

    Physical health status will be assessed using the CRIUGM Self-AdMinistered questionnaire (CESAM).

    The CESAM has been previously developed and validated.

    It is composed of 20 items exploring several domains:

    • weight loss and its extent;
    • polypharmacy defined by a number of therapeutic classes taken on a daily basis ≥ 5;
    • vision, hearing, and memory problems;
    • use of home support;
    • 6-item activities of daily living scale, 4-item instrumental activities of daily living scale;
    • mood assessed
    • regular physical activity defined as at least 1 hour per week in the past month;
    • and history of falls in the past 12 months.

    The CESAM provides two complementary scores:

    1. An overall frailty score ranging from 0 to 18
    2. A four-stage categorization of frailty

    This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

    Measured: 3 months

  2. Social Isolation

    Social isolation will be assessed using the 11-item Duke Social Support Index (DSSI).

    This index includes two subscales:

    • social interaction (i.e., frequency of interactions)
    • subjective support (i.e., satisfaction with emotional support provided).

    The DSSI score ranges from 11 to 33, with higher scores indicating higher levels of social inclusion. Scores for the 11 items are combined and categorized as low (score ≤26), high (score 27-29), and very high (score 30-33). We will use the mean score of the 11-item DSSI and its breakdown into three categories as the primary outcome.

    This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

    Measured: 3 months

  3. Prescribing context

    Researchers will also study the prescribing context. A document will be filled by primary care physicians to give additional informations on the prescribing context such as the date of the prescription and the reason of the prescription.

    Measured: 3 months

  4. Satisfaction from the visit to the museum

    A short questionnaire will be given to participants to the intervention at the end of the visit to the museum. This questionnaire will give additionnal information on the satisfaction from the visit and whether the visit was made alone or accompanied.

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jul 2022
  2. Study start27 Jun 2022
  3. Primary completion21 Jul 2023
  4. Study completion22 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
This study is experimental, prospective, open-label, non-randomized, pre-post intervention with a single group of participants who will be their own control.
Masking
None (open label)
Enrolment
86 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05445453
Sponsor's protocol ID
MP-53-2023-2627
Acronym
PM
Status last verified
Feb 2024
First submitted
30 Jun 2022
Last updated
23 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Beauchet O, Moret A, Deveault M, Thiboutot C, Parent N, Boyer H, Galery K. Physician-prescribed museum visit benefits on mental health: results of an experimental study. Front Med (Lausanne). 2025 May 14;12:1590145. doi: 10.3389/fmed.2025.1590145. eCollection 2025.

    PubMed 40438362

Questions about this trial

What is this clinical trial studying?

A study testing Museum visit in people with Quality of Life and Social Isolation, run by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quality of life (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05445453, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
PM Clinical Trial NCT05445453 | AzTrials